| Title |
Suvorexant: a promising, novel treatment for insomnia
|
|---|---|
| Published in |
Neuropsychiatric Disease and Treatment, February 2016
|
| DOI | 10.2147/ndt.s31495 |
| Pubmed ID | |
| Authors |
Joyce K Lee-Iannotti, James M Parish |
| Abstract |
Suvorexant a novel, orexin receptor antagonist was recently approved by the US Food and Drug Administration for the treatment of sleep onset and sleep maintenance insomnia in August 2014. Multiple animal and human studies support the efficacy, safety, and tolerability of suvorexant for patients of various profiles. Current recommendations advocate for a starting dose of 10 mg and a maximum dose of 20 mg, with cautious use in women, obese patients, and patients taking other CYP3A4 inhibitors. More head-to-head studies comparing suvorexant to other sedative-hypnotic therapies are needed to further delineate which patients will benefit the most from this medication over others. |
X Demographics
The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 25% |
| Unknown | 3 | 75% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 2 | 50% |
| Members of the public | 2 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 56 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 56 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 11 | 20% |
| Researcher | 6 | 11% |
| Student > Master | 5 | 9% |
| Student > Doctoral Student | 4 | 7% |
| Other | 4 | 7% |
| Other | 7 | 13% |
| Unknown | 19 | 34% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 7 | 13% |
| Pharmacology, Toxicology and Pharmaceutical Science | 6 | 11% |
| Agricultural and Biological Sciences | 5 | 9% |
| Biochemistry, Genetics and Molecular Biology | 3 | 5% |
| Neuroscience | 3 | 5% |
| Other | 5 | 9% |
| Unknown | 27 | 48% |
Attention Score in Context
This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 February 2024.
All research outputs
#6,275,200
of 25,371,288 outputs
Outputs from Neuropsychiatric Disease and Treatment
#790
of 3,132 outputs
Outputs of similar age
#93,770
of 406,412 outputs
Outputs of similar age from Neuropsychiatric Disease and Treatment
#24
of 71 outputs
Altmetric has tracked 25,371,288 research outputs across all sources so far. Compared to these this one has done well and is in the 75th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,132 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.6. This one has gotten more attention than average, scoring higher than 74% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 406,412 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 76% of its contemporaries.
We're also able to compare this research output to 71 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 66% of its contemporaries.